LSTA:NASDAQ
Lisata Therapeutics, Inc.
$1.09
0.00%
(0.00) 1D
Nov 17, 11:39:03โฏAM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LSTA...
Open
$1.08
High
$1.10
Low
$1.00
Mkt. cap
11.78M
Avg. vol.
135.12K
Volume
224.85K
52-wk high
$5.06
52-wk low
$0.96
EPS
-$1.64
Beta
1.04
Shares outstanding
10.80M
No. of employees
21
Open
$1.08
High
$1.10
Low
$1.00
Mkt. cap
11.78M
Avg. vol.
135.12K
Volume
224.85K
52-wk high
$5.06
52-wk low
$0.96
EPS
-$1.64
Beta
1.04
Shares outstanding
10.80M
No. of employees
21
News stories
From web sources and news partners
ChartMill
·
1 hour ago
S&P 500 Stocks Gapping Down in Today's Session
TradingView
·
2 hours ago
Wells Fargo sets 2027 S&P 500 year-end target at 8,200
qz.com
·
4 hours ago
5 Nasdaq-linked stock indexes and how each differs from the S&P 500
Traders Union
·
31 minutes ago
S&P 500 trades near AVWAP and key retracement lines, Chris Ciovacco notes
Profile
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
About Lisata Therapeutics, Inc.
CEO-
Employees21
Founded1980
HeadquartersBasking Ridge, New Jersey, United States
SectorHealth Care
IndustryBiotechnology
Websitelisata.com